{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Hsu CC"],"funding":["Taipei Veterans General Hospital","National Science and Technology Council"],"pagination":["518-528"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10550875"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["56(4)"],"pubmed_abstract":["<h4>Background</h4>The effectiveness and safety of direct oral anticoagulants (DOACs) in patients with atrial fibrillation (AF) and advanced kidney disease (AKD) has not been fully established.<h4>Objectives</h4>To determine the effectiveness and safety related to pooled or specific DOACs to that with warfarin in patients with AF and AKD.<h4>Methods</h4>Patients with AF and AKD (estimated glomerular filtration rate < 30 mL/min) who received DOAC or warfarin from July 2011 to December 2020 were retrospectively identified in a medical center in Taiwan. Primary outcomes were hospitalized for stroke/systemic embolism and major bleeding. Secondary outcomes included any ischemia and any bleeding.<h4>Results</h4>A total of 1,011 patients were recruited, of whom 809 (80.0%) were in the DOACs group"],"journal":["Journal of thrombosis and thrombolysis"],"pubmed_title":["Effectiveness and safety of direct oral anticoagulants versus warfarin in patients with atrial fibrillation and advanced kidney disease."],"pmcid":["PMC10550875"],"funding_grant_id":["V111B-043, V111EA-017","MOST111-2635-B-075-001"],"pubmed_authors":["Chou CY","Hsu CC","Wang SF","Chen KH","Chang YL","Chen CC","Chang SL"],"additional_accession":[]},"is_claimable":false,"name":"Effectiveness and safety of direct oral anticoagulants versus warfarin in patients with atrial fibrillation and advanced kidney disease.","description":"<h4>Background</h4>The effectiveness and safety of direct oral anticoagulants (DOACs) in patients with atrial fibrillation (AF) and advanced kidney disease (AKD) has not been fully established.<h4>Objectives</h4>To determine the effectiveness and safety related to pooled or specific DOACs to that with warfarin in patients with AF and AKD.<h4>Methods</h4>Patients with AF and AKD (estimated glomerular filtration rate < 30 mL/min) who received DOAC or warfarin from July 2011 to December 2020 were retrospectively identified in a medical center in Taiwan. Primary outcomes were hospitalized for stroke/systemic embolism and major bleeding. Secondary outcomes included any ischemia and any bleeding.<h4>Results</h4>A total of 1,011 patients were recruited, of whom 809 (80.0%) were in the DOACs group","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Nov","modification":"2026-06-02T19:02:37.199Z","creation":"2025-04-19T07:15:25.016Z"},"accession":"S-EPMC10550875","cross_references":{"pubmed":["37452906"],"doi":["10.1007/s11239-023-02859-x"]}}